Treatment May Help Lung Cancer Outcomes
Posted on: Friday, 29 June 2007, 18:05 CDT
Patients with inoperable non-small cell lung cancer who get a high chemotherapy dose before treatment may have a better outcome, says a U.S. study.
Researchers at the M.D. Anderson Cancer Center in Houston wanted to test the efficacy of giving a high dose of chemotherapy before chemoradiation begins. Induction chemotherapy is when doctors administer medicine to stop the growth of the cancer in the lungs from spreading to other parts of the body.
A total of 265 patients with inoperable non-small cell lung cancer were divided into two groups; one group of 127 patients received the induction therapy and the chemoradiation, with the second group of 138 treated with chemoradiation alone.
The researchers found a small but significant increase in overall survival in the patients who received the induction therapy with chemoradiation versus the chemoradiation-only group.
Those patients who received induction therapy as part of their treatment saw an increase in overall survival by an average of six months as compared to the group who did not receive the initial dose of chemotherapy, according to the study published in the July 1 issue of the International Journal of Radiation Oncology Biology Physics.
Source: United Press International
Related Articles
- Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients With Anemia Due to Chemotherapy at FDA ODAC Meeting
- Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
- Keynote Lecture on Hyperthermia Therapy Receives Standing Ovation at Biannual Meeting of the German Cancer Society
- Sutter Solano Cancer Center Offers Oncology Patients Customized Cancer Treatment
- Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
- Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
- FDA Approves FRAGMIN(R) As First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients With Cancer
- Cephalon Receives FDA Approval of FENTORA(TM) (Fentanyl Buccal Tablet) for the Management of Breakthrough Pain in Patients With Cancer
- Cephalon Receives Approvable Letter for FENTORA(TM) (Fentanyl Buccal Tablet) for Management of Breakthrough Pain in Patients With Cancer
- Clinical Laboratory Assessment of Hepatitis C and HIV Coinfected Patients According to the Antiretroviral Therapy Received
User Comments (0)
RSS Feeds